Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVENUE: Faricimab in Neovascular AMD
NCT02484690Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2015
- Primary completion
- Sep 2017
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of faricimab in neovascular age-related macular degeneration (NVAMD), sponsored by Roche. Started Aug 2015; status: completed.
02
Drugs
faricimab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02484690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484690.